AEGiS-PRn: HIV, Flu & HBV/HCV Focus of Antiviral Drug Discovery Conference on March 15-16, 2000, in New Jersey PRNewswireImportant note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.
Click here to return to PRNewswire main menu
DonateNow


HIV, Flu & HBV/HCV Focus of Antiviral Drug Discovery Conference on March 15-16, 2000, in New Jersey

PRNewswire - December 8, 1999


PRINCETON, N.J., Dec. 8 /PRNewswire/ -- Pharmaceutical industry advances in the discovery and development of novel antiviral agents in HIV, influenza/respiratory, and hepatitis B & C, will be presented in depth on March 15-16, 2000 at the Hyatt Regency Hotel in Princeton, NJ, announces Strategic Research Institute.

The conference will feature work in the neuraminidase inhibitor area presented by Roche (Tamiflu), Glaxo Wellcome (Relenza), and RW Johnson PRI (RWJ-270201), Agouron's protease inhibitor for rhinovirus infection, and clinical summary of ViroPharma's Pleconaril, a novel therapy for picornaviral disease.

In HIV, the conferences focuses on Trimeris' fusion inhibitor, T-20 and Merck's Integrase inhibitor; also featured will be reverse transcriptase inhibitors, plus contributions from other companies.

The HBV/HCV section will feature discussion of Schering Plough's Ribavirin, Roche's Pegainterferon alfa-2a and contributions from Eli Lilly and Glaxo Wellcome; Emory University and Novirio Pharmaceuticals will present new data on nucleoside analogs and L-nucleosides, both having shown potent activity against hepatitis B.

To request the agenda and/or register, please contact Camille Coward of Strategic Research at ccoward@srinstitute.com or by phone at 212-967-0095, ext 255.

SOURCE Strategic Research Institute

CONTACT: Camille Coward of Strategic Research, ccoward@srinstitute.com, 212-967-0095, ext 255/

Web Site: http://www.srinstitute.com/
991213
PR991213


Copyright © 1999 - PRNewswire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through PRNewswire, Permissions, 810 Seventh Ave., 32nd Floor, New York, NY 10019  http://www.prnewswire.com.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.

Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .